Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Novavax ( (NVAX) ) has issued an update.
On May 27, 2025, Novavax, Inc. announced the elimination of the Chief Operating Officer position, resulting in the termination of John Trizzino’s employment effective June 20, 2025. Following his departure, Mr. Trizzino will continue to provide consulting services to the company until December 31, 2025, under a new consulting agreement. The separation agreement includes a lump sum payment and COBRA premium coverage for Mr. Trizzino, while the consulting agreement ensures a monthly fee and continued vesting of his equity awards.
The most recent analyst rating on (NVAX) stock is a Buy with a $19.00 price target. To see the full list of analyst forecasts on Novavax stock, see the NVAX Stock Forecast page.
Spark’s Take on NVAX Stock
According to Spark, TipRanks’ AI Analyst, NVAX is a Neutral.
Novavax’s stock shows potential with strong revenue growth and profitability improvements, supported by strategic partnerships and recent FDA approval. However, financial instability, regulatory challenges, and market penetration issues weigh on the stock. Valuation metrics suggest upside potential, yet technical indicators advise caution.
To see Spark’s full report on NVAX stock, click here.
More about Novavax
Average Trading Volume: 8,364,141
Technical Sentiment Signal: Sell
Current Market Cap: $1.17B
See more data about NVAX stock on TipRanks’ Stock Analysis page.